Literature DB >> 30988964

Clinical Aspects, Immunophenotypic Analysis and Survival Rate of Chronic Lymphocytic Leukaemia Patients in Erbil City, Iraq.

Kawa M Hasan1,2.   

Abstract

OBJECTIVES: Chronic lymphocytic leukaemia (CLL) is characterised by an accumulation of clonal B cells in the blood, bone marrow and lymphatic tissue. This study aimed to evaluate the clinical and immunophenotypic characteristics and survival rate of CLL patients.
METHODS: This retrospective study was conducted at the Nanakaly Hospital for Blood Diseases & Oncology in Erbil, Iraq, between January 2011 and December 2017. A total of 105 CLL patients were assessed to determine clinical presentation and staging, immunophenotype and survival rate.
RESULTS: The median age of the patients was 65 years and 63.8% were male. The main clinical presentations were splenomegaly (64.8%), pallor (61.9%) and lymphadenopathy (60%). More than half of the patients presented at an advanced clinical stage according to the Rai and Binet staging systems (59.1% and 55.2%, respectively). All CLL cases expressed both cluster of differentiation (CD)19 and CD5, 67.6% had monoclonal kappa light chains and 21% expressed CD38. The five-year overall survival (OS) rate was 61.3%. The mean duration of five-year survival was 41.3 months (95% confidence interval: 36.4-46.3 months). There were no correlations between survival and sociodemographic, clinical or laboratory characteristics.
CONCLUSION: In comparison to the existing Western literature, Iraqi CLL patients more frequently presented with hepatosplenomegaly and at a more advanced clinical stage. In addition, the five-year OS rate was much lower.

Entities:  

Keywords:  Chronic Lymphocytic Leukemia; Immunophenotyping; Iraq; Lymphoproliferative Disorders; Survival Rates

Mesh:

Year:  2019        PMID: 30988964      PMCID: PMC6443287          DOI: 10.18295/squmj.2018.18.04.006

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  24 in total

1.  What is changing in the natural history of chronic lymphocytic leukemia?

Authors:  S Molica; D Levato
Journal:  Haematologica       Date:  2001-01       Impact factor: 9.941

2.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

3.  Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.

Authors:  Julio Delgado; Estella Matutes; Alison M Morilla; Ricardo M Morilla; Kwasi A Owusu-Ankomah; Furheen Rafiq-Mohammed; Ilaria del Giudice; Daniel Catovsky
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

Review 4.  Sex differences in incidence and outcome of chronic lymphocytic leukemia patients.

Authors:  Stefano Molica
Journal:  Leuk Lymphoma       Date:  2006-08

5.  Prognosis related to staging systems for chronic lymphocytic leukemia.

Authors:  J R de Faria; J S de Oliveira; R M Delbone de Faria; M R Silva; S Goihman; M Yamamoto; J Kerbauy
Journal:  Sao Paulo Med J       Date:  2000-07-06       Impact factor: 1.044

Review 6.  Chronic lymphocytic leukemia: recent advances in diagnosis and treatment.

Authors:  Brian L Abbott
Journal:  Oncologist       Date:  2006-01

7.  Immunoglobulin light chain repertoire in chronic lymphocytic leukemia.

Authors:  Kostas Stamatopoulos; Chrysoula Belessi; Anastasia Hadzidimitriou; Tatjana Smilevska; Evangelia Kalagiakou; Katerina Hatzi; Niki Stavroyianni; Anastasia Athanasiadou; Aliki Tsompanakou; Theodora Papadaki; Garyfallia Kokkini; George Paterakis; Riad Saloum; Nikolaos Laoutaris; Achilles Anagnostopoulos; Athanasios Fassas
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

Review 8.  Disease burden of chronic lymphocytic leukaemia within the European Union.

Authors:  Louise Watson; Peter Wyld; Daniel Catovsky
Journal:  Eur J Haematol       Date:  2008-07-08       Impact factor: 2.997

9.  Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.

Authors:  Mohammad Hojjat Farsangi; Mahmood Jeddi-Tehrani; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Ahmad Shamsian Khoramabadi; Hodjatallah Rabbani; Fazel Shokri
Journal:  Iran J Immunol       Date:  2008-03       Impact factor: 1.603

10.  Chronic lymphocytic leukemia in Turkey: experience of a single center in Istanbul.

Authors:  Omer Nuri Pamuk; Gülsüm Emel Pamuk; Teoman Soysal; Seniz Ongören; Zafer Başlar; Burhan Ferhanoğlu; Yildiz Aydin; Birsen Ulkü; Gulten Aktuğlu; Nuran Akman
Journal:  South Med J       Date:  2004-03       Impact factor: 0.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.